Thursday - April 02, 2026

Category Archives: Pharmaceuticals & Biotech

Exosomes Clinical Trial Pipeline Appears Robust With 80+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Exosomes Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Exosomes Pipeline … Continue reading →

Dilated Cardiomyopathy Clinical Trial Pipeline Appears Robust With 8+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Dilated Cardiomyopathy Pipeline Insight 2026” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Dilated Cardiomyopathy pipeline landscape. It covers the Dilated Cardiomyopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading →

Glioma Clinical Trial Pipeline Appears Robust With 180+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s “Glioma Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the glioma pipeline landscape. It covers the Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Glioma therapeutics … Continue reading →

COVID-19 Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “COVID-19 Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in COVID-19 pipeline landscape. It covers the COVID-19 pipeline drug profiles, including clinical and nonclinical stage products. It also covers the COVID-19 therapeutics assessment … Continue reading →

CAR-T Clinical Trial Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “CAR T-Cell Therapy Pipeline Insight 2026” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the CAR T-Cell Therapy pipeline landscape. It covers the CAR T-Cell Therapy Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Alzheimer’s Disease Clinical Trial Pipeline Shows Potential with Active Contributions from 200+ Key Companies | DelveInsight

DelveInsight’s, “Alzheimer’s disease Pipeline Insight, 2026” report provides comprehensive insights about 200+ companies and 220+ pipeline drugs in Alzheimer’s disease pipeline landscape. It covers the Alzheimer’s Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

AAV Vectors in Gene Therapy Clinical Trial Pipeline Accelerates as 180+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline Insight, 2026” report provides comprehensive insights about 180+ companies and 250+ pipeline drugs in AAV Vectors in Gene Therapy pipeline landscape. It covers the AAV Vectors in Gene Therapy pipeline drug … Continue reading →

Systemic Sclerosis Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Systemic Sclerosis Pipeline Insight 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Systemic Sclerosis pipeline landscape. It covers the Systemic Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →